This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Industrial Technology Research Institute. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Hsiang-Ching Wang: Innovator in Antibody Research
Introduction
Hsiang-Ching Wang is a prominent inventor based in Hsinchu, Taiwan. He has made significant contributions to the field of antibody research, particularly in the development of innovative therapeutic agents. With a total of 2 patents, Wang's work has the potential to impact medical treatments significantly.
Latest Patents
Wang's latest patents include groundbreaking inventions in the realm of antibodies. The first patent is for an anti-human epidermal growth factor receptor (EGFR) antibody. This invention includes an amino acid sequence as set forth in SEQ ID No. 3. The antibody is designed to bind to a labeling agent, which can be used for labeling cells. Additionally, a novel method for screening an anti-EGFR antibody is provided. The second patent focuses on an anti-human transferrin receptor antibody. This patent details an amino sequence of a heavy chain variable region represented by SEQ ID NO.: 1 or SEQ ID NO.: 2. The anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
Career Highlights
Hsiang-Ching Wang is affiliated with the Industrial Technology Research Institute, where he conducts his research and development activities. His work at this esteemed institution has allowed him to explore various innovative approaches in antibody technology.
Collaborations
Wang collaborates with notable colleagues, including Ming-Hua Yang and Min-Yuan Chou. These partnerships enhance the research environment and foster innovation in their projects.
Conclusion
Hsiang-Ching Wang is a distinguished inventor whose work in antibody research is paving the way for new therapeutic solutions. His contributions are vital to advancing medical science and improving patient outcomes.